IAVI brings together in-house researchers on infectious and neglected diseases, public and private partners, and local communities to develop and deliver globally accessible vaccines and antibodies.
For more than 20 years, IAVI and its global network of partners have been working to develop an HIV vaccine. This goal remains as important today as ever. In 2019, nearly 2 million people acquired HIV, according to the latest data from the Joint United Nations Programme on HIV/AIDS. Experts warn that without significant progress in reducing HIV transmission, the HIV/AIDS epidemic will likely worsen as the largest generation of young people enters the age at which they are at highest risk of HIV acquisition. We need new ways to stop the spread of HIV, and chief among these is a vaccine.
Since 2018, IAVI has applied its vaccine development expertise to emerging infectious diseases (EIDs) and tuberculosis (TB). These EIDs include COVID-19, Lassa fever, and Marburg virus disease. With the acquisition in 2018 of the clinical assets and staff of Aeras, the tuberculosis vaccine development product development partnership, IAVI has advanced clinical development of several new TB investigational vaccines. In 2019, one of these candidates — M72/AS01E, developed in partnership with GSK — was shown in a Phase II trial to be 50% effective at preventing development of TB disease in people already infected with TB bacteria.
IAVI’s antibody discovery and optimization platform, originally developed for HIV research, now encompasses preclinical and clinical research on monoclonal antibodies for the prevention and treatment of a variety of diseases, including HIV, COVID-19, and snakebite envenoming.
HIV Vaccines
IAVI scientists and their collaborators are pursuing innovative strategies to design vaccine immunogens capable of inducing durable immunity against HIV.
Vaccine Design and Development Laboratory
Brooklyn, N.Y.
Neutralizing Antibody Center
Scripps Research, La Jolla, Calif.
HIV vaccine efforts herald a new era of vaccinology
IAVI Report commentary by IAVI CEO Mark Feinberg
bnAbs for HIV Prevention
Broadly neutralizing antibodies (bnAbs), if shown to be effective, will augment existing HIV prevention tools and help limit the spread of HIV until a vaccine is developed. IAVI and partners have several bnAb candidates in development.
Neutralizing Antibody Center
Scripps Research, La Jolla, Calif.
HIV epidemiology
The research protocols that yielded bnAbs
Tuberculosis Vaccines
Recent vaccine research has demonstrated promise that a new approach to TB prevention is possible. IAVI is partnering in clinical trials of several novel TB vaccine candidates.
Turning the tide on TB?
IAVI Report article on the potential advances in treating and preventing TB
Emerging Infectious Diseases Vaccines and Therapeutics
IAVI has a robust preclinical vaccine pipeline to address outbreak pathogens, including, in partnership with Merck, SARS-CoV-2, the virus that causes COVID-19.
Snakebite
IAVI and partners have formed a consortium to develop affordable and accessible monoclonal antibodies to treat snakebite envenoming.
